Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors
Open Access
- 11 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 22 (10) , 1238-1249
Abstract
Background: In postmenopausal women diagnosed with breast cancer (BC), most BC tumors are hormone receptor positive and guidelines recommend adjuvant endocrine therapy that includes an aromatase inhibitor (AI). This study investigates the impact of a 6-week, home-based, self-directed walking program on the commonly reported side effect of AI-associated arthralgia (AIAA). Materials and Methods: In this phase II trial, consented BC patients were randomized to walking Intervention (n = 31) or Wait List Control (WLC; n = 31). Eligibility criteria included: stage 0–III BC, on AI for at least 4 weeks, ≥3 on a 5-point scale inquiring about joint symptom intensity “at its worst,” and exercising ≤150 minutes per week. Outcomes were self-reported joint symptoms and psychosocial measures. Analyses comparing Intervention and WLC groups were conducted on an intention-to-treat basis to assess intervention impact at 6 weeks (postintervention) and at 6-months follow-up. Adjusted means were calculated to assess differences in two groups. Results: In our final sample (n = 62), mean age was 64 years, 74% were white, and 63% had a body mass index of 30 or higher. At postintervention, Intervention group participants reported significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living (ADL), and less perceived helplessness in managing joint symptoms. At 6-months follow-up (postwalking period in both Intervention and WLC), walking minutes per week had decreased significantly; however, improvements in stiffness and difficulty with ADLs were maintained. Conclusion: This study adds to the growing evidence base suggesting exercise as a safe alternative or adjunct to medications for the management of AIAA.Keywords
Funding Information
- National Cancer Institute (1R21CA169492-01A)
This publication has 27 references indexed in Scilit:
- Aquatic exercise in a chest-high pool for hormone therapy-induced arthralgia in breast cancer survivors: a pragmatic controlled trialClinical Rehabilitation, 2012
- Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerBreast Cancer Research and Treatment, 2011
- The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008Journal of Clinical Epidemiology, 2010
- American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Oncology Practice, 2010
- Recent AdvancesThe Cancer Journal, 2010
- Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast CancerJournal of Clinical Oncology, 2007
- Life of the mind: The interface of psychopharmaceuticals, domestic economies, and social abandonmentAmerican Ethnologist, 2004
- Measures of self-efficacy, helplessness, mastery, and control: The Arthritis Helplessness Index (AHI)/Rheumatology Attitudes Index (RAI), Arthritis Self-Efficacy Scale (ASES), Children's Arthritis Self-Efficacy Scale (CASE), Generalized Self-Efficacy Scale (GSES), Mastery Scale, Multi-Dimensional Health Locus of Control Scale (MHLC), Parent's Arthritis Self-Efficacy Scale (PASE), Rheumatoid Arthritis Self-Efficacy Scale (RASE), and Self-Efficacy Scale (SES)Arthritis & Rheumatism, 2003
- Self-Efficacy and the Stages of Exercise Behavior ChangeResearch Quarterly for Exercise and Sport, 1992
- Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scalePain, 1983